Skip to main
AUTL

Autolus Therapeutics (AUTL) Stock Forecast & Price Target

Autolus Therapeutics (AUTL) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Autolus Therapeutics PLC is positioned for growth due to its robust clinical-stage pipeline, which features multiple promising T-cell therapies, including Obe-cel, that may demonstrate enhanced efficacy compared to standard-of-care CAR-T options. The company expects to achieve substantial improvements in manufacturing efficiencies, potentially driving gross margins upward to 60-70% over time. The demonstrated safety and mortality benefits of its lead therapy, Aucazyl, in real-world applications further solidify its competitive advantage and potential for increased market adoption in treating refractory acute lymphoblastic leukemia.

Bears say

Autolus Therapeutics faces significant challenges, as projected sales are anticipated to remain flat in the third quarter of 2025 due to recent changes in CMS reimbursement policies. The company's development of CAR-T therapeutics appears to be insufficient, with early clinical results indicating potential shortfalls in production capability and effectiveness. Additionally, the emergence of patient relapses and minimal reductions in disease scores raise concerns about the reliability of their therapies, further contributing to a negative outlook on the stock.

Autolus Therapeutics (AUTL) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Autolus Therapeutics (AUTL) Forecast

Analysts have given Autolus Therapeutics (AUTL) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Autolus Therapeutics (AUTL) has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Autolus Therapeutics (AUTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.